Clinical Trial Update: Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib with or without bevacizumab in stage IV non-small cell lung cancer with EGFR mutations has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R | Phase 2 | Status: COMPLETED | Results posted: 2019-12-26